Dakshinamoorthy A, Asmita A, Senapati S
ACS Omega. 2023; 8(11):9748-9763.
PMID: 36969469
PMC: 10034783.
DOI: 10.1021/acsomega.2c08279.
Sherry D, Worth R, Sayed Y
Adv Exp Med Biol. 2021; 1371:79-108.
PMID: 34351572
DOI: 10.1007/5584_2021_655.
Potempa M, Lee S, Yilmaz N, Nalivaika E, Rogers A, Spielvogel E
J Mol Biol. 2018; 430(24):5182-5195.
PMID: 30414407
PMC: 6292680.
DOI: 10.1016/j.jmb.2018.10.022.
Fun A, Wensing A, Verheyen J, Nijhuis M
Retrovirology. 2012; 9:63.
PMID: 22867298
PMC: 3422997.
DOI: 10.1186/1742-4690-9-63.
Kipp D, Hirschi J, Wakata A, Goldstein H, Schramm V
Proc Natl Acad Sci U S A. 2012; 109(17):6543-8.
PMID: 22493227
PMC: 3340095.
DOI: 10.1073/pnas.1202808109.
Role of Gag in HIV Resistance to Protease Inhibitors.
Clavel F, Mammano F
Viruses. 2011; 2(7):1411-1426.
PMID: 21994687
PMC: 3185719.
DOI: 10.3390/v2071411.
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Dam E, Quercia R, Glass B, Descamps D, Launay O, Duval X
PLoS Pathog. 2009; 5(3):e1000345.
PMID: 19300491
PMC: 2652074.
DOI: 10.1371/journal.ppat.1000345.
Molecular mechanisms of FIV infection.
Elder J, Sundstrom M, de Rozieres S, de Parseval A, Grant C, Lin Y
Vet Immunol Immunopathol. 2008; 123(1-2):3-13.
PMID: 18289701
PMC: 2409060.
DOI: 10.1016/j.vetimm.2008.01.007.
Isolation and characterization of recombinant Drosophila Copia aspartic proteinase.
Athauda S, Yoshioka K, Shiba T, Takahashi K
Biochem J. 2006; 399(3):535-42.
PMID: 16813567
PMC: 1615899.
DOI: 10.1042/BJ20060800.
Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease.
Pettit S, Clemente J, Jeung J, Dunn B, Kaplan A
J Virol. 2005; 79(16):10601-7.
PMID: 16051852
PMC: 1182631.
DOI: 10.1128/JVI.79.16.10601-10607.2005.
Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.
Pettit S, Henderson G, Schiffer C, Swanstrom R
J Virol. 2002; 76(20):10226-33.
PMID: 12239298
PMC: 136535.
DOI: 10.1128/jvi.76.20.10226-10233.2002.
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease.
King N, Melnick L, Prabu-Jeyabalan M, Nalivaika E, Gao Y, Nie X
Protein Sci. 2002; 11(2):418-29.
PMID: 11790852
PMC: 2373441.
DOI: 10.1110/ps.25502.
Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.
Trylska J, Antosiewicz J, Geller M, Hodge C, Klabe R, Head M
Protein Sci. 1999; 8(1):180-95.
PMID: 10210196
PMC: 2144115.
DOI: 10.1110/ps.8.1.180.
An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir.
Melnick L, Yang S, Rossi R, Zepp C, Heefner D
Antimicrob Agents Chemother. 1998; 42(12):3256-65.
PMID: 9835523
PMC: 106031.
DOI: 10.1128/AAC.42.12.3256.
Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication.
Serio D, Rizvi T, Cartas M, Kalyanaraman V, Weber I, KOPROWSKI H
Proc Natl Acad Sci U S A. 1997; 94(7):3346-51.
PMID: 9096396
PMC: 20372.
DOI: 10.1073/pnas.94.7.3346.
Synergistic binding of inhibitors to the protease from HIV type 1.
Asante-Appiah E, Chan W
Biochem J. 1996; 315 ( Pt 1):113-7.
PMID: 8670094
PMC: 1217158.
DOI: 10.1042/bj3150113.
Sensitive, hydrosoluble, macromolecular fluorogenic substrates for human immunodeficiency virus 1 proteinase.
Anjuere F, Monsigny M, Lelievre Y, Mayer R
Biochem J. 1993; 291 ( Pt 3):869-73.
PMID: 8489513
PMC: 1132449.
DOI: 10.1042/bj2910869.
Development of activity assays for high-volume evaluation of human immunodeficiency virus (HIV) protease inhibitors in rat serum: results with ditekiren.
Wilkinson K, Rush B, Sharma S, Evans D, Ruwart M, Friis J
Pharm Res. 1993; 10(4):562-6.
PMID: 8483839
DOI: 10.1023/a:1018950003185.
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
Otto M, Garber S, Winslow D, Reid C, ALDRICH P, Jadhav P
Proc Natl Acad Sci U S A. 1993; 90(16):7543-7.
PMID: 8356053
PMC: 47178.
DOI: 10.1073/pnas.90.16.7543.
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.
Otto M, Reid C, Garber S, Lam P, Scarnati H, Bacheler L
Antimicrob Agents Chemother. 1993; 37(12):2606-11.
PMID: 8109924
PMC: 192753.
DOI: 10.1128/AAC.37.12.2606.